Will Herrington (@willkidney) 's Twitter Profile
Will Herrington

@willkidney

Prof@Oxford_NDPH, Hon.Nephrologist, EMPA-KIDNEY & EASi-KIDNEY CI. Join the fight against CKD, systematic bias & random error: make studies larger & randomized!

ID: 725642252991758336

linkhttps://www.ndph.ox.ac.uk/team/will-herrington calendar_today28-04-2016 11:06:09

624 Tweet

1,1K Followers

626 Following

Gunnar Henrik Heine (@gunnar_heine) 's Twitter Profile Photo

APPLAUSE, APPLAUSE Vlado Perkovic Jonathan Barratt Brad H Rovin et al Iptacopan reduces proteinurie (PU) in IgA NP 🐘1: Is the effect additive to SGLT2I (low use in APPLAUSE) 🐘2: How long to treat with iptacopan? 🐘3: Will low PU be longterm renoprotective? nejm.org/doi/full/10.10…

APPLAUSE, APPLAUSE <a href="/VladoPerkovic/">Vlado Perkovic</a> <a href="/IgAN_JBarratt/">Jonathan Barratt</a> <a href="/BradRovin/">Brad H Rovin</a> et al
Iptacopan reduces proteinurie (PU) in IgA NP
🐘1: Is the effect additive to SGLT2I (low use in APPLAUSE)
🐘2: How long to treat with iptacopan?
🐘3: Will low PU be longterm renoprotective?
nejm.org/doi/full/10.10…
Will Herrington (@willkidney) 's Twitter Profile Photo

Nice summary from the Oxford Population Health (OxPop) team: “ …while empagliflozin continues to have some benefit after stopping treatment, the effects are smaller than when taking empagliflozin and short lived. Maximising the benefits of such medicines in #CKD requires long-term treatment.’

Will Herrington (@willkidney) 's Twitter Profile Photo

It was 50% not on KRT by end of 2y post-EMPA-K not treated with #SGLT2i. Regulators globally have been so supportive with accelerated review. We clinicians need 2 b as fast with implementation. Open-label extension studies ought 2 b the norm (thx for flozinator badge Swapnil Hiremath @hswapnil.medsky.social)

Oxford Population Health (OxPop) (@oxford_ndph) 's Twitter Profile Photo

Want to know more about #clinicaltrials? Apply for our part-time #MSc in Clinical Trials to receive in-depth training in conducting large-scale, randomised clinical trials from world leading experts. 🎓 Apply now 👉 buff.ly/3UviNW8

Want to know more about #clinicaltrials? 

Apply for our part-time #MSc in Clinical Trials to receive in-depth training in conducting large-scale, randomised clinical trials from world leading experts. 🎓

Apply now 👉 buff.ly/3UviNW8
Nephrology Journal Club (@nephjc) 's Twitter Profile Photo

We're going back...to the future of #FLOZINATION!! This #NephJC we'll discuss long-term effects of empagliflozin on CKD & revisit the EMPA-KIDNEY study participants. Join us 11/5/24 at 9pm EST or 11/6/24 at 9pm IST. nephjc.com/news/empa-long…

NDT (@ndtsocial) 's Twitter Profile Photo

🎥Watch Dr Kaitlin Mayne present the NDT publication: Empagliflozin lowers serum uric acid in CKD: exploratory analyses from the EMPA-KIDNEY trial In only 3 minutes, Kaitlin Mayne gives the main results of this study: oup.cloud.panopto.eu/Panopto/Pages/…

Brendon Neuen (@brendonneuen) 's Twitter Profile Photo

Important care gap highlighted by the EMPA KIDNEY post-trial follow up: 1 in 4 people with diabetes on SGLT2i who were hospitalised for #heartfailure didnt restart SGLT2i within 12 months of discharge SGLT2i discontinuation analysis led by Tamie Milder: dom-pubs.onlinelibrary.wiley.com/doi/10.1111/do…

Sreejith Parameswaran (@sreejithdr) 's Twitter Profile Photo

Joel M. Topf, MD FACP & Roger Rodby killing it on stage as 'Sherlock Holmes' & 'John Watson' (by turn) at the ApEx Pathsala, Mumbai, teaching how to solve Fluid & Electrolyte mysteries!! Exceptionally Enlightening & Entertaining!!

<a href="/kidney_boy/">Joel M. Topf, MD FACP</a> &amp; <a href="/NephRodby/">Roger Rodby</a> killing it on stage as 'Sherlock Holmes' &amp; 'John Watson' (by turn) at the ApEx Pathsala, Mumbai, teaching how to solve Fluid &amp; Electrolyte mysteries!!
Exceptionally Enlightening &amp; Entertaining!!
Radcliffe Cardiology (@radcliffecardio) 's Twitter Profile Photo

Prof Will Herrington discusses the EMPA-KIDNEY trial on long-term effects of #empagliflozin in patients with #CKD. 📽️Watch here👉 ow.ly/f15x50UomXA #SGLT2 #CardioRenal #CVRM #CardioTwitter

NEJM (@nejm) 's Twitter Profile Photo

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation. nej.md/40sCr7s

ASN Publications (@asnpublications) 's Twitter Profile Photo

Editors’ Choice 2024: Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial This study's findings support the use of sodium-glucose cotransporter-2 inhibitors in CKD, irrespective of frailty, multimorbidity, or

Editors’ Choice 2024: Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial

This study's findings support the use of sodium-glucose cotransporter-2 inhibitors in CKD, irrespective of frailty, multimorbidity, or
Will Herrington (@willkidney) 's Twitter Profile Photo

If you haven’t heard why Oxford Renal Studies Grp believe innovations in conduct of trials r more important than developing surrogates & new analytic methods then this is your bedtime read 4 tonight!!! Not exhilarating, until you see the magic of examples. academic.oup.com/ndt/article/40…

Prof Kamlesh Khunti (@kamleshkhunti) 's Twitter Profile Photo

Great to see post trial follow-up of a CVOT! EMPAKIDNEY Empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. NEJM

Great to see post trial follow-up of a CVOT!

EMPAKIDNEY 

Empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued.

<a href="/NEJM/">NEJM</a>